NYSEAMERICAN:LCTX Lineage Cell Therapeutics (LCTX) Stock Price, News & Analysis $1.07 +0.01 (+0.94%) Closing price 04:10 PM EasternExtended Trading$1.08 +0.01 (+0.56%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock About Lineage Cell Therapeutics Stock (NYSEAMERICAN:LCTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get LCTX alerts:Sign Up Key Stats Today's Range$1.05▼$1.0950-Day Range$1.03▼$1.3552-Week Range$1.00▼$2.09Volume1.13 million shsAverage Volume966,960 shsMarket Capitalization$270.61 millionP/E RatioN/ADividend YieldN/APrice Target$6.25Consensus RatingBuy Company Overview Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations. Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration. In parallel, Lineage is advancing oligodendrocyte progenitor cell therapies for spinal cord injury and conducting early-stage programs in immune-effector cell oncology, including dendritic cell-based vaccines and natural killer-cell products intended to stimulate or enhance anti-tumor responses. Founded in the 1990s as BioTime and rebranded in late 2019, Lineage Cell Therapeutics is headquartered in Carlsbad, California, with research and development activities extending into clinical sites across the United States and Europe. The company’s leadership team is led by President and Chief Executive Officer Brian Culley, supported by an experienced scientific advisory board. Through its integrated development strategy, Lineage aims to translate stem cell science into scalable therapies that address significant unmet medical needs in ophthalmology, neurology and oncology.AI Generated. May Contain Errors. Read More Lineage Cell Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreLCTX MarketRank™: Lineage Cell Therapeutics scored higher than 50% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingLineage Cell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and no sell ratings.Upside PotentialLineage Cell Therapeutics has a consensus price target of $6.25, representing about 484.1% upside from its current price of $1.07.Amount of Analyst CoverageLineage Cell Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Lineage Cell Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Lineage Cell Therapeutics are expected to grow in the coming year, from ($0.08) to ($0.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lineage Cell Therapeutics is -5.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lineage Cell Therapeutics is -5.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLineage Cell Therapeutics has a P/B Ratio of 4.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.52% of the float of Lineage Cell Therapeutics has been sold short.Short Interest Ratio / Days to CoverLineage Cell Therapeutics has a short interest ratio ("days to cover") of 26.2, which indicates bearish sentiment.Change versus previous monthShort interest in Lineage Cell Therapeutics has recently decreased by 1.03%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLineage Cell Therapeutics does not currently pay a dividend.Dividend GrowthLineage Cell Therapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.02 News SentimentLineage Cell Therapeutics has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Lineage Cell Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for LCTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows4 people have added Lineage Cell Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lineage Cell Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders24.70% of the stock of Lineage Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions62.47% of the stock of Lineage Cell Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lineage Cell Therapeutics' insider trading history. Receive LCTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LCTX Stock News HeadlinesLineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call TranscriptAugust 14 at 10:07 AM | finance.yahoo.comQ3 EPS Estimate for Lineage Cell Therapeutics Cut by AnalystAugust 13 at 1:43 AM | americanbankingnews.comMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night. Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets.August 14 at 1:00 AM | Paradigm Press (Ad)Lineage Cell Therapeutics Balances Progress and RiskAugust 12 at 10:07 PM | theglobeandmail.comLineage Cell Therapeutics, Inc. (LCTX) Q2 2026 Earnings Call TranscriptAugust 7, 2026 | seekingalpha.comLineage Cell Therapeutics maps COR1 path with 'thaw and inject' cell therapy planJuly 14, 2026 | msn.comLineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease TranscriptJuly 13, 2026 | seekingalpha.comLineage Cell Therapeutics (LCTX) Stock Faces Mixed Analyst Target Changes After Fresh CoverageJune 20, 2026 | finance.yahoo.comSee More Headlines LCTX Stock Analysis - Frequently Asked Questions How have LCTX shares performed this year? Lineage Cell Therapeutics' stock was trading at $1.67 at the start of the year. Since then, LCTX stock has decreased by 35.9% and is now trading at $1.07. How were Lineage Cell Therapeutics' earnings last quarter? Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) announced its earnings results on Thursday, August, 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by $0.00. The company earned $1.07 million during the quarter, compared to analysts' expectations of $1.84 million. Lineage Cell Therapeutics had a negative trailing twelve-month return on equity of 73.06% and a negative net margin of 246.58%. Read the conference call transcript. Who are Lineage Cell Therapeutics' major shareholders? Lineage Cell Therapeutics' top institutional investors include BlackRock Inc. (5.29%), Defender Capital LLC. (2.65%), Bank of New York Mellon Corp (0.16%) and Flputnam Investment Management Co. (0.12%). Insiders that own company stock include Broadwood Partners, LP, Brian M Culley, Don M Bailey and Jill Ann Howe. View institutional ownership trends. How do I buy shares of Lineage Cell Therapeutics? Shares of LCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lineage Cell Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lineage Cell Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Moderna (MRNA), JPMorgan Chase & Co. (JPM) and Chevron (CVX). Company Calendar Last Earnings8/06/2026Today8/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 LCTX's financial health is in the Yellow zone, according to TradeSmith. LCTX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSEAMERICAN:LCTX CIK876343 Webwww.lineagecell.com Phone(442) 287-8963Fax510-521-3389Employees60Year FoundedN/APrice Target and Rating Average Price Target for Lineage Cell Therapeutics$6.25 High Price Target$9.00 Low Price Target$3.00 Potential Upside/Downside+484.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$63.53 million Net Margins-246.58% Pretax Margin-285.75% Return on Equity-73.06% Return on Assets-30.87% Debt Debt-to-Equity RatioN/A Current Ratio6.61 Quick Ratio6.89 Sales & Book Value Annual Sales$14.56 million Price / Sales18.59 Cash FlowN/A Price / Cash FlowN/A Book Value$0.24 per share Price / Book4.46Miscellaneous Outstanding Shares252,910,000Free Float190,439,000Market Cap$270.61 million OptionableNot Optionable Beta1.53 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NYSEAMERICAN:LCTX) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersAI insiders stockpile guns, gold & gas masksKeith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...TradeSmith | SponsoredWall Street is staring at the wrong AI tradeAnthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredWho Really Gets Rich from IPOs?Peter Thiel turned a $500,000 stake in Meta into nearly $1 billion by investing eight years before its IPO. Tr...Weiss Ratings | SponsoredHow a rare metal shortage sent gains up 2512 percentIn 2010, a rare earth metal called dysprosium surged 2,512 percent in two and a half years after China cut exp...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lineage Cell Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lineage Cell Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
